Related references
Note: Only part of the references are listed.Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P. Martin et al.
ANNALS OF ONCOLOGY (2008)
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma
D. S. Ritchie et al.
ANNALS OF HEMATOLOGY (2007)
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Peter Dreger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
B. S. Kahl et al.
ANNALS OF ONCOLOGY (2006)
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas - Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
Christina Nickenig et al.
CANCER (2006)
Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma
Noel Laudi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Improved survival of follicular lymphoma patients in the United States
WT Swenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma
YL Kasamon et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
J Mangel et al.
ANNALS OF ONCOLOGY (2004)
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma:: a prospective, multicenter phase II study
W Brugger et al.
ANNALS OF ONCOLOGY (2004)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
AM Gianni et al.
BLOOD (2003)
Outcome of autologous transplantation for mantle cell lymphoma:: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant registries
E Vandenberghe et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
AK Gopal et al.
BLOOD (2002)
Frontline transplantation of autologous CD34+ selected blood cells for advanced mantle cell lymphoma:: no evidence of longterm cure:: a single centre experience
P Jindra et al.
BONE MARROW TRANSPLANTATION (2000)
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study
D Decaudin et al.
BONE MARROW TRANSPLANTATION (2000)
Autologous hematopoietic stem cell transplantation for mantle cell lymphoma
JM Vose et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
Dexa-BEAM: An effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma
A Josting et al.
LEUKEMIA & LYMPHOMA (2000)
Share Paper
